A detailed history of Ubs Group Ag transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 24,915 shares of LYRA stock, worth $4,484. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,915
Previous 14,697 69.52%
Holding current value
$4,484
Previous $4,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.24 - $0.34 $2,452 - $3,474
10,218 Added 69.52%
24,915 $6,000
Q2 2024

Aug 13, 2024

BUY
$0.26 - $6.25 $3,816 - $91,743
14,679 Added 81550.0%
14,697 $4,000
Q1 2024

May 13, 2024

SELL
$4.55 - $6.53 $21,758 - $31,226
-4,782 Reduced 99.63%
18 $0
Q4 2023

Feb 09, 2024

BUY
$2.82 - $5.24 $13,485 - $25,057
4,782 Added 26566.67%
4,800 $25,000
Q2 2023

Aug 11, 2023

SELL
$1.98 - $4.33 $1,653 - $3,615
-835 Reduced 97.89%
18 $0
Q1 2023

May 12, 2023

SELL
$1.95 - $3.09 $4,960 - $7,860
-2,544 Reduced 74.89%
853 $1,000
Q4 2022

Feb 08, 2023

BUY
$2.44 - $5.42 $739 - $1,642
303 Added 9.79%
3,397 $10,000
Q3 2022

Nov 10, 2022

BUY
$4.95 - $6.6 $5,306 - $7,075
1,072 Added 53.02%
3,094 $15,000
Q2 2022

Aug 10, 2022

BUY
$4.12 - $7.51 $8,256 - $15,050
2,004 Added 11133.33%
2,022 $11,000
Q1 2022

May 16, 2022

SELL
$3.5 - $5.36 $14,182 - $21,718
-4,052 Reduced 99.56%
18 $0
Q4 2021

Feb 14, 2022

BUY
$4.22 - $9.41 $17,099 - $38,129
4,052 Added 22511.11%
4,070 $18,000
Q3 2021

Nov 15, 2021

SELL
$6.06 - $9.43 $3,326 - $5,177
-549 Reduced 96.83%
18 $0
Q2 2021

Aug 13, 2021

SELL
$6.91 - $12.59 $15,112 - $27,534
-2,187 Reduced 79.41%
567 $5,000
Q1 2021

May 12, 2021

SELL
$10.38 - $15.61 $8,957 - $13,471
-863 Reduced 23.86%
2,754 $32,000
Q4 2020

Feb 11, 2021

BUY
$9.28 - $13.88 $25,696 - $38,433
2,769 Added 326.53%
3,617 $41,000
Q3 2020

Nov 12, 2020

SELL
$10.61 - $13.96 $9,209 - $12,117
-868 Reduced 50.58%
848 $9,000
Q2 2020

Jul 31, 2020

BUY
$10.91 - $18.56 $18,721 - $31,848
1,716 New
1,716 $19,000

Others Institutions Holding LYRA

About Lyra Therapeutics, Inc.


  • Ticker LYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,826,400
  • Market Cap $5.73M
  • Description
  • Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...
More about LYRA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.